Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist NGS Methylation Detection System, a robust, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome.
DNA methylation plays a key role in many biological processes including cancer. When present on a single nucleotide, a methyl group can alter genetic behavior without changing the DNA sequence. Analyzing these methylation patterns provides unique understanding of disease pathology, including the ability to screen for cancer earlier using blood samples known as “liquid biopsies.”
“Methylation is one of the most interesting and informative epigenetic modifications due to its wide-reaching effects, but historically it has been difficult to study efficiently,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “In partnership with New England Biolabs, we’ve developed a ...
